1386979-55-0 Usage
Description
Mirk-IN-1, also known as TC-S 7004, is a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A/B (DYRK1A/B) inhibitor. It is a small molecule compound that has been developed to target and inhibit the activity of DYRK1A/B, which are protein kinases involved in various cellular processes.
Uses
Used in Pharmaceutical Industry:
Mirk-IN-1 is used as a therapeutic agent for the treatment of various diseases and conditions. The inhibition of DYRK1A/B by Mirk-IN-1 can potentially lead to the regulation of cellular processes and the modulation of signaling pathways, making it a promising candidate for the development of new drugs.
Used in Research Applications:
Mirk-IN-1 is also used as a research tool in the field of molecular biology and pharmacology. It can be employed to study the role of DYRK1A/B in various cellular processes and to investigate the potential therapeutic effects of inhibiting these kinases in different disease models.
Used in Drug Development:
Mirk-IN-1 serves as a lead compound in the development of new drugs targeting DYRK1A/B. Its structure and activity can be further optimized to improve its potency, selectivity, and pharmacokinetic properties, leading to the development of more effective and safer drugs for the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1386979-55-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,6,9,7 and 9 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1386979-55:
(9*1)+(8*3)+(7*8)+(6*6)+(5*9)+(4*7)+(3*9)+(2*5)+(1*5)=240
240 % 10 = 0
So 1386979-55-0 is a valid CAS Registry Number.
1386979-55-0Relevant articles and documents
Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
Anderson, Kevin,Chen, Yi,Chen, Zhi,Dominique, Romyr,Glenn, Kelli,He, Yang,Janson, Cheryl,Luk, Kin-Chun,Lukacs, Christine,Polonskaia, Ann,Qiao, Qi,Railkar, Aruna,Rossman, Pamela,Sun, Hongmao,Xiang, Qing,Vilenchik, Masha,Wovkulich, Peter,Zhang, Xiaolei
, p. 6610 - 6615 (2014/01/06)
DYRK1B is a kinase over-expressed in certain cancer cells (including colon, ovarian, pancreatic, etc.). Recent publications have demonstrated inhibition of DYRK1B could be an attractive target for cancer therapy. From a data-mining effort, the team has discovered analogues of pyrido[2,3-d]pyrimidines as potent enantio-selective inhibitors of DYRK1B. Cells treated with a tool compound from this series showed the same cellular effects as down regulation of DYRK1B with siRNA. Such effects are consistent with the proposed mechanism of action. Progress of the SAR study is presented.
